Corpus overview


MeSH Disease

Cysts (2)

Nevus (1)

Conjunctivitis (1)

Papilloma (1)

Polyps (1)

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page

    COVID-19 receptor ACE2 is expressed in human conjunctival tissue, expecially in diseased conjunctival MESHD tissue

    Authors: shengjie li Sr.; danhui li; jianchen fang; qiang liu; xinghuai sun; gezhi xu; wenjun cao

    doi:10.1101/2020.05.21.20109652 Date: 2020-05-23 Source: medRxiv

    COVID-19 virus has currently caused major outbreaks worldwide. ACE2 is a major cellular-entry receptor for the COVID-19 virus. Although ACE2 is known to be expressed in many organs, whether it is expressed by the conjunctival tissue is largely unknown. Human conjunctival tissues from 68 subjects were obtained, which included 10 subjects with conjunctival nevi MESHD nevi HP, 20 subjects with conjunctivitis MESHD conjunctivitis HP, 9 subjects with conjunctival papilloma MESHD papilloma HP, 16 subjects with conjunctival cyst MESHD, 7 subjects with conjunctival polyps MESHD, and 6 ocular traumas as normal subjects. Expression of ACE2 was evaluated by immunohistochemistry, immunofluorescence, reverse transcriptase-quantitative polymerase chain reaction, and western blot assay. We observed the expression of ACE2 by conjunctival tissues, expecially in conjunctival epithelial cells. ACE2 was significantly (p<0.001) overexpressed in conjunctival cells obtained from subjects with conjunctivitis MESHD conjunctivitis HP, conjunctival nevi MESHD nevi HP, conjunctival papilloma MESHD papilloma HP, conjunctival cyst MESHD, and conjunctival polyps MESHD epithelial cells when compared to that in conjunctival epithelial cells obtained from control subjects. Collectively, clinical features of reported COVID-19 patients combined with our results indicate that COVID-19 is likely to be transmitted through the conjunctiva.

    Clinical and Imaging Findings in COVID-19 Patients Complicated by Pulmonary Embolism MESHD Pulmonary Embolism HP

    Authors: Ting Li; Gregory Kicska; Paul E Kinahan; Chengcheng Zhu; Murat Alp Oztek; Wei Wu

    doi:10.1101/2020.04.20.20064105 Date: 2020-04-24 Source: medRxiv

    Objective: To describe clinical, and imaging findings including the evolution pattern in COVID-19 pneumonia MESHD pneumonia HP complicated by pulmonary embolism MESHD pulmonary embolism HP (PE). Methods: Eleven of 1453 patients with a probable diagnosis of COVID-19 pneumonia MESHD pneumonia HP were retrospectively selected for the presence of PE. Clinical and laboratory data were recorded. All cross-sectional CT imaging was qualitatively scored for the first 28 days after onset of symptoms TRANS. Results: Of 24 patients underwent CTA-PE, 11 were confirmed with PE. All 11 patients developed acute respiratory distress HP syndrome MESHD (ARDS). We observed an evolution pattern of predominant findings with ground-glass opacities (GGO) to GGO with crazy paving in 3 patients, then to consolidation with linear densities, or to reticulation in 9 patients. Lung cysts MESHD or traction bronchiectasis MESHD bronchiectasis HP could be seen from day 5 to 9 after symptoms and reticulation, subpleural curvilinear lines were more common from day 20. The pulmonary opacities HP were predominantly peripheral in distribution with relative sparing of nondependent lungs. The severity of lung involvement was high with an average score of 9.7 in the first phase, 18 in the second phase plateauing in the next two phases, with a slight decrease to 16.9 in the late phase. The pulmonary emboli were most common in segmental and subsegmental pulmonary arteries. Conclusion: The incidence of PE among suspected patients in COVID-19 was high. Our study suggests PE may occur with increased frequency in the ARDS subgroup. The evolution of radiographic abnormalities showed a general pattern, but are also unique with more extensive lung injury MESHD and specific imaging features.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.